Mode
Text Size
Log in / Sign up

Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRDNew guidelines help doctors tell delirium from dementia

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that emerging blood-based biomarkers and imaging are rapidly changing the diagnosis and management of ADRD.

This clinical guideline provides a narrative review regarding the diagnosis, imaging, and treatment of Alzheimer's disease and related dementia (ADRD). The scope covers patients presenting with memory loss or cognitive performance concerns across primary care, emergency department, and general neurology settings.

The authors synthesize that the diagnostic and treatment landscape for ADRD is undergoing rapid change due to advancements in imaging and blood-based biomarkers. A key distinction is noted between delirium, which is typically an acute or subacute fluctuating change in mental status, and dementia, which is characterized as a chronic progressive presentation of cognitive change.

While specific trial data are not provided, the guideline emphasizes that acute care systems must become knowledgeable regarding treatment courses and potential complications as more amyloid-modifying therapies are administered. The evidence suggests an evolving landscape for clinical management in both acute and chronic settings.

How this fits prior evidence

This guideline addresses a gap in the clinical management of Alzheimer's disease by highlighting how rapid changes in blood-based biomarkers and imaging are transforming the diagnostic landscape. It complements previous findings regarding the role of ceramides as a challenging target in Alzheimer's pathology and the impact of the MIND diet on cognitive scores in adults with high biomarker levels.

A new clinical guideline helps doctors distinguish between delirium and dementia in patients with memory or thinking problems. Delirium is typically an acute or subacute fluctuating change in mental status, while dementia is a chronic progressive cognitive decline. The guideline covers diagnosis, imaging, and treatment of Alzheimer's disease and related dementias (ADRD) in primary care, emergency departments, and neurology settings.

The guideline notes that the field of ADRD diagnosis and treatment is changing rapidly, especially with new imaging and blood-based biomarkers. As more amyloid-modifying therapies become available, acute care systems need to be aware of potential complications and treatment courses.

This is a narrative review and expert opinion, not a new study. It does not report specific numbers or compare treatments. The main takeaway is that clinicians should carefully assess whether a patient's confusion is due to delirium or dementia, as the two conditions require different approaches.

For patients and families, this guideline reinforces the importance of a thorough evaluation when memory or cognitive concerns arise. If you or a loved one experiences sudden confusion, seek medical attention promptly, as delirium may be reversible.

What this means for you:
Delirium and dementia have different patterns: delirium is acute and fluctuating, dementia is chronic and progressive.

Common questions

What is the difference between delirium and dementia?

Delirium is typically an acute or subacute fluctuating change in mental status, while dementia is a chronic progressive presentation of cognitive change. The new guideline helps doctors tell them apart.

Who are these guidelines for?

The guidelines are for healthcare providers in primary care, emergency departments, and general neurology settings who see patients with memory loss or cognitive performance concerns.

Are there new treatments for Alzheimer's disease?

The guideline notes that diagnosis, management, and therapy of Alzheimer's disease and related dementias are undergoing rapid change, especially with new imaging and blood-based biomarkers and amyloid-modifying therapies.

Study Details

Study typeGuideline
EvidenceLevel 5
PublishedJun 2026
View Original Abstract ↓
ImportanceThe patient presenting with memory loss often requires a complex, extensive multidisciplinary specialty evaluation that may begin in the primary care, emergency department, or general neurology setting. The analysis begins with a suspicion or concern regarding cognitive performance raised by the patient, family, or provider. Ideally, a better understanding will empower the primary care and general neurology communities to screen for and appropriately diagnose, treat, or refer patients with dementia.MethodsThe thematic focus of this narrative review is diagnosis, imaging, and treatment of Alzheimer’s disease and related dementia (ADRD). Information was abstracted from the National Library of Medicine MEDLINE/PubMed database. Medical Subject Headings (MeSH) heading search terms included dementia and, more specifically, Alzheimer’s disease. The search targeted primary research, preferentially compared to reviews, consensus statements, or case reports if feasible.ObservationsDelirium typically represents an acute or subacute fluctuating change in mental status, often temporally related to acute illness. While dementia is typically associated with a more chronic progressive presentation of cognitive change without the presence of concurrent illness. However, subacute or dementia presentations may be exacerbated in that setting as well.Conclusion and relevanceThe diagnosis, management, and therapy of Alzheimer’s disease and related dementia is undergoing rapid change in imaging and now the utility of blood-based biomarkers. As more amyloid-modifying therapy is administered, the acute care systems should be knowledgeable of the treatment course and potential for complications.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.